Claims Data & Patient Journey: Missing Insights
- Pharmaceutical firms are increasingly focused on how therapies are used by patients in the real world.
- Noah Nasser, CEO of datma, emphasized the limitations of relying solely on claims data.
- Without a complete picture, quantifying the impact of diagnostic testing on treatment outcomes becomes challenging.
Traditional claims data often falls short. This leaves crucial diagnostic context missing, hindering effective understanding of the patient journey, a critical element in driving appropriate market access. Learn why pharmaceutical firms are increasingly focused on real-world patient therapy use. Discover how federated data models provide deeper insights into patient care and how precision medicine is shifting market access strategies. Integrating molecular insights with existing claims data illuminates treatment delays and patient outcomes, ensuring the most effective therapies reach those who need them. News directory 3 explores the limitations of relying solely on claims data, and delves into how new approaches are revolutionizing insight. Discover what’s next for improving patient care and access.
Precision Medicine drives New Market Access Strategies
Updated June 18, 2025
Pharmaceutical firms are increasingly focused on how therapies are used by patients in the real world. Understanding the patient journey requires more than just traditional claims data, which often misses key clinical and diagnostic details. A more complete view of care pathways is essential for improving therapy adoption and optimizing market access.
Noah Nasser, CEO of datma, emphasized the limitations of relying solely on claims data. While useful for tracking procedures and medication fills, this data often lacks the context needed to understand treatment timing and clinical decision-making. This lack of diagnostic context can hinder market access teams trying to understand therapy adoption.
Without a complete picture, quantifying the impact of diagnostic testing on treatment outcomes becomes challenging. Questions about treatment delays and patient drop-off points remain challenging to answer. understanding variations in physician behavior across different regions also requires data beyond what claims data can provide.
To address these gaps, federated data models are emerging as a promising solution. These systems allow data to remain within each institution’s control while enabling queries across multiple sources. By capturing structured data from laboratory and pathology systems,these models offer insights into test timing,molecular assay outcomes,and subsequent care sequences. Integrating these insights with claims data provides a more thorough view of the patient journey, allowing for better-informed market access strategies.
nasser noted that while claims data remains foundational, augmenting it with structured diagnostic insights is crucial. This integrated approach helps illuminate blind spots in the patient journey, ensuring that precision medicine innovations reach the patients who need them most.
What’s next
The industry is moving toward models that preserve institutional control while unlocking deeper, more granular data. This shift promises to connect the full care journey,from diagnosis to treatment,leading to more effective and equitable access to life-changing therapies and improved real-world data analysis.